3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
68
Leukemia
56
Myelodysplastic Syndromes
53
Lymphoma
47
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Lymphoma, Non-Hodgkin
43
Multiple Myeloma
40
Hodgkin Disease
39
Leukemia, Lymphocytic, Chronic, B-Cell
35
Congenital Abnormalities
30
Lymphoma, Follicular
28
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Mantle-Cell
26
Neoplasms, Plasma Cell
25
Lymphoma, B-Cell, Marginal Zone
24
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23
Burkitt Lymphoma
23
Myeloproliferative Disorders
22
Lymphoma, Large-Cell, Immunoblastic
22
Leukemia, Myelomonocytic, Chronic
22
Blast Crisis
22
Leukemia, Myeloid, Chronic-Phase
21
Leukemia, Myeloid, Accelerated Phase
21
Primary Myelofibrosis
19
Lymphoma, T-Cell, Cutaneous
15
Hematologic Neoplasms
15
Graft vs Host Disease
15
Dendritic Cell Sarcoma, Interdigitating
14
Anemia, Refractory, with Excess of Blasts
14
Waldenstrom Macroglobulinemia
13
Interventions
fludarabine phosphate
2
Cyclophosphamide
2
AP 1903 reagent
2
fludarabine
1
Whole-Body Irradiation
1
Peripheral Blood Stem Cell Transplantation
1
Mesna
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thalassemia
×
Busulfan
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts